Zacks: Brokerages Anticipate Theravance Biopharma Inc (TBPH) to Post -$1.18 Earnings Per Share

Brokerages expect that Theravance Biopharma Inc (NASDAQ:TBPH) will report ($1.18) earnings per share for the current quarter, Zacks reports. Three analysts have provided estimates for Theravance Biopharma’s earnings, with the lowest EPS estimate coming in at ($1.26) and the highest estimate coming in at ($1.02). Theravance Biopharma reported earnings per share of ($1.27) during the same quarter last year, which would indicate a positive year-over-year growth rate of 7.1%. The firm is expected to issue its next quarterly earnings results on Tuesday, November 6th.

On average, analysts expect that Theravance Biopharma will report full-year earnings of ($4.41) per share for the current year, with EPS estimates ranging from ($4.70) to ($4.22). For the next fiscal year, analysts forecast that the company will report earnings of ($4.29) per share, with EPS estimates ranging from ($5.09) to ($3.72). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that follow Theravance Biopharma.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Wednesday, August 1st. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.20) by $0.44. Theravance Biopharma had a negative return on equity of 261.70% and a negative net margin of 640.07%. The business had revenue of $23.48 million during the quarter, compared to the consensus estimate of $9.97 million.

A number of analysts have issued reports on the company. ValuEngine raised Theravance Biopharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 9th. Piper Jaffray Companies reissued an “overweight” rating and issued a $55.00 target price on shares of Theravance Biopharma in a research report on Wednesday, August 1st. Needham & Company LLC reissued a “buy” rating and issued a $40.00 target price on shares of Theravance Biopharma in a research report on Wednesday, August 1st. Cantor Fitzgerald set a $55.00 target price on Theravance Biopharma and gave the stock a “buy” rating in a research report on Wednesday, August 1st. Finally, BidaskClub raised Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. Theravance Biopharma has an average rating of “Hold” and a consensus price target of $40.00.

In other news, EVP Bradford J. Shafer sold 31,300 shares of the firm’s stock in a transaction on Wednesday, August 8th. The stock was sold at an average price of $27.94, for a total value of $874,522.00. Following the completion of the transaction, the executive vice president now directly owns 127,606 shares of the company’s stock, valued at $3,565,311.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Renee D. Gala sold 43,743 shares of the firm’s stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $26.79, for a total value of $1,171,874.97. The disclosure for this sale can be found here. Insiders sold 99,223 shares of company stock valued at $2,627,208 over the last three months. Company insiders own 6.90% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. UBS Group AG boosted its holdings in shares of Theravance Biopharma by 88.4% in the first quarter. UBS Group AG now owns 4,511 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 2,117 shares during the period. SG Americas Securities LLC bought a new position in shares of Theravance Biopharma in the first quarter worth $130,000. Xact Kapitalforvaltning AB bought a new position in shares of Theravance Biopharma in the first quarter worth $202,000. Royal Bank of Canada boosted its holdings in shares of Theravance Biopharma by 22.3% in the first quarter. Royal Bank of Canada now owns 16,664 shares of the biopharmaceutical company’s stock worth $404,000 after acquiring an additional 3,042 shares during the period. Finally, Millennium Management LLC bought a new position in shares of Theravance Biopharma in the fourth quarter worth $419,000. 85.92% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:TBPH traded up $0.21 during trading hours on Wednesday, reaching $27.85. The stock had a trading volume of 123,994 shares, compared to its average volume of 306,450. The company has a debt-to-equity ratio of 6.52, a current ratio of 4.14 and a quick ratio of 3.95. Theravance Biopharma has a 12-month low of $21.27 and a 12-month high of $35.90. The company has a market capitalization of $1.50 billion, a P/E ratio of -5.11 and a beta of 1.80.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

Featured Article: Price to Earnings Ratio (PE)

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply